Supernus Pharmaceuticals (SUPN) Projected to Post Earnings on Monday

Supernus Pharmaceuticals (NASDAQ:SUPN) is anticipated to release its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect Supernus Pharmaceuticals to post earnings of $0.35 per share and revenue of $175.8230 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:30 PM ET.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN opened at $52.83 on Monday. The firm has a market capitalization of $2.96 billion, a PE ratio of 45.94 and a beta of 0.78. The firm’s 50-day moving average is $46.87 and its two-hundred day moving average is $38.02. Supernus Pharmaceuticals has a 1 year low of $29.16 and a 1 year high of $53.28.

Analyst Ratings Changes

A number of brokerages have issued reports on SUPN. TD Cowen boosted their price target on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 17th. Cantor Fitzgerald upped their target price on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 30th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Supernus Pharmaceuticals in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $62.67.

Insiders Place Their Bets

In related news, SVP Frank Mottola sold 14,000 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $44.51, for a total value of $623,140.00. Following the completion of the transaction, the senior vice president directly owned 15,496 shares of the company’s stock, valued at $689,726.96. This represents a 47.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Timothy C. Dec sold 11,780 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $44.49, for a total value of $524,092.20. Following the completion of the transaction, the chief financial officer directly owned 1,246 shares of the company’s stock, valued at $55,434.54. This trade represents a 90.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 362,741 shares of company stock valued at $16,390,592. 8.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at approximately $51,000. Raymond James Financial Inc. acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at approximately $55,000. Osaic Holdings Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 211.5% in the second quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company’s stock valued at $63,000 after acquiring an additional 1,328 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Supernus Pharmaceuticals by 255.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,245 shares of the specialty pharmaceutical company’s stock valued at $134,000 after acquiring an additional 3,051 shares during the period. Finally, Creative Planning acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at approximately $242,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.